-
The Production Process of Calicheamicin γ1I
Time of Update: 2023-04-27
Nuclear Magnetic Resonance (NMR) Spectroscopy: The Production Process of Calicheamicin γ1I: An Overview of Chemical Synthesis and Purification Techniques Calicheamicin γ1I is an important antibiotic used in the treatment of cancer and other diseases.
-
The Instruction of bk-EBDP
Time of Update: 2023-04-27
This process involves the use of bidentate phosphorus ligands, which are capable of coordinating to two different metal centers, to catalyze the reaction between chlorine and ethylene.
-
Performance is gradually showing: lipid-lowering "artifact" Novartis oligonucleotide new drug PCSK9 with 2 injections a year
Time of Update: 2023-02-05
com; Some new PCSK9 drugsInclisiran is injected subcutaneously twice a yearInclisiran is injected subcutaneously twice a yearOn June 28, 2020, the clinical application IND of the PCSK9 small molecule interfering RNA (siRNA, Small Interfering RNA Drug) cholesterol-lowering drug inclisiran, pioneered by Novartis, was accepted by CDE in China for the first time 。 Novartis acquired The Medicines Company in November 2019 through the acquisition of The Medicines Company for US$9.
-
Advance payment of $21.5 million: Insilico and Sanofi enter into a strategic collaboration for new drug development
Time of Update: 2023-02-05
5 million and target nomination fees for up to six targets, additional R&D and commercial milestone payments, and phased royalties ranging from medium to low double digitsInsilico, a clinical-stage drug discovery company powered by artificial intelligence (AI), announced a multi-year strategic research collaboration with Sanofi for multiple targets.
-
Created in China, the first bispecific antibody evaluation report is coming!
Time of Update: 2023-02-05
com shows that Candonilimab injection (R&D code: AK104) was approved by the National Medical Products Administration (NMPA) of China in June 2022 for the treatment of recurrent or metastatic cervical cancer (R/M CC) that has failed previous platinum-containing chemotherapy patient, became the world's first approved PD-1/CTLA-4 bispecific antibody.
-
Insilico is about to release a new Pharma.AI artificial intelligence drug discovery platform
Time of Update: 2023-02-05
Insilico Medicine is an innovative drug discovery company driven by end-to-end artificial intelligence (AI) that uses modern machine learning technologies such as generative adversarial networks (GANs), deep reinforcement learning (RL), and pre-trained models (Transformers) to connect generative biology, generative chemistry and clinical trial analysis 。 Since its establishment, it has built Pharma.
-
How the "magic bullet" technology flow helps optimize the ADC drug conjugation process
Time of Update: 2023-02-05
：“” | ADCNote: This article does not constitute any investment advice and recommendations, subject to official/company announcements; This article is only an introduction to medical and health-related
-
Satan leader: Tianyu Pharmaceutical bursts with great energy and continues to evolve
Time of Update: 2023-02-05
Under the dual role of market demand and the company's strategy, Tianyu achieved revenue of 813 million yuan in 2017 for blood pressure-lowering APIs and intermediates, increased to 1.
-
Zhai Lingyun, chairman of Nanjing Xinbai, won the award of the best chairman of listed company
Time of Update: 2023-02-03
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
-
Genting Xinyao announced that the Center for Drug Evaluation of the National Medical Products Administration of China intends to include Nefecon as a priority review for the treatment of primary IgA nephropathy
Time of Update: 2023-02-03
HK), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative drugs and vaccines to address unmet medical needs in Greater China and other Asian regions, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) announced its intention to transfer Nefecon on its official website on December 26 (budesonide late-release capsules) for the treatment of adult patients with primary IgA nephropathy at risk of disease are included in the priority review.
-
Genting Xinyao will hold an online investor conference for the company's new strategy launch
Time of Update: 2023-02-03
/* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prnews
-
The FDA approved a second new drug to slow down Alzheimer's disease, lecanemab
Time of Update: 2023-02-02
"Unclear impactLecanemab is authorized under the FDA's "accelerated approval" pathway, which specializes in treating diseases with few treatments; It also does not require phase III clinical trial data.
-
The patient monitor was approved for marketing
Time of Update: 2023-02-02
Recently, the State Medical Products Administration approved the registration application for the innovative product "patient monitor" produced by Shenzhen Keman Medical Equipment Co. , Ltd. after re
-
What role can antiviral small and medium-sized molecule drugs play? Expert answers
Time of Update: 2023-02-02
Wang Guiqiang, director of the Department of Infectious Diseases of Peking University First Hospital, pointed out at the meeting that the use of antiviral oral small molecule drugs can help patients reduce the risk of severe disease and hospitalization, and even reduce the risk of death, but the indications should be strictly mastered and used under the guidance of doctors.
-
After the medical waste disposal has made up for the shortcomings, what are the new demands?
Time of Update: 2023-02-01
"Spring Festival Time" opened, and many related topics were on the hot search, which is enough to prove its attention. Recently, many people are also concerned about the large-scale movement of peopl
-
The market size of pharmaceutical intermediates may exceed 350 billion! Wastewater treatment methods continue to innovate and break through
Time of Update: 2023-02-01
"The long synthesis step, complex intermediates, and stable molecular structure make the wastewater composition of pharmaceutical intermediates very complex, containing a large number of toxic, refractory organic compounds, as well as Cl-, SO42- and other inorganic salts," the industry said, pharmaceutical intermediate wastewater has the characteristics of high COD, high ammonia nitrogen, high salt and high color, which is one of the major difficulties in the current chemical environmental protection work.
-
Pharmaceutical companies in many places are at full capacity to ensure supply, and VOCs governance cannot be left behind
Time of Update: 2023-02-01
In addition, the standard specifically puts forward the requirements for fugitive emission of VOCs, pointing out that pharmaceutical companies should adopt a closed operation mode and configure a complete VOCs collection and purification treatment device.
-
After the medical waste disposal has made up for the shortcomings, what are the new demands?
Time of Update: 2023-02-01
Then, in April, the "Implementation Plan for Capacity Building of Centralized Medical Waste Disposal Facilities" was introduced, followed by May, the National Health Commission, the Ministry of Ecology and Environment, the Ministry of Industry and Information Technology and other seven departments jointly issued the "Notice on Carrying out Special Rectification of Waste in Medical Institutions", that is, from May to December.
-
The State Food and Drug Administration accepted the marketing application of Dizhesuvortinib, and the national innovative drug broke through the refractory target of lung cancer
Time of Update: 2023-02-01
/* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prnews
-
Huang Guo investigates the progress of new crown vaccine drug research and development in Beijing
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];ntenteditable="false" style="border-top:1px dashed rgb(255, 0, 0); color:rgb(255, 255, 255); display:block; font-size:0px; height:0px; left:20px; line-height:0px; margin:0px; padding:0px; position:absolute; top:165px; user-select:none; width:703px; z-index:9999">ntenteditable="false" style="-webkit-border-radius:2px; background:url( center no-repeat #ff0000; border-radius:2px; color:#fff; cursor:pointer; display:block; font-size:0px; height:17px; line-height:0px; margin:0px; padding:0px; position:absolute; right:17px; top:-8px; width:17px; z-index:9999" title="Insert paragraph here">↵ On January 11, Huang Guo, Deputy Director of the State Food and Drug Administration, led a team to Sinopharm China Biotechnology Co.
